Current topics about cardiovascular adverse events occurred during cancer drug therapy

Cardiovascular adverse effects during itraconazole therapy.

Itraconazole has been widely used in the treatment of fungal disease including chronic necrotising pulmonary aspergillosis (CNPA) [1, 2]. Its use has been associated with occasional reports of adverse cardiovascular events including congestive heart failure [3], hypertension (HT) [4], premature ventricular contractions [5] and even ventricular fibrillation [6]. However, these adverse effects ha...

Adverse cardiovascular drug interactions.

Adverse drug events during AKI and its recovery.

BACKGROUND AND OBJECTIVES The impact of AKI on adverse drug events and therapeutic failures and the medication errors leading to these events have not been well described. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS A single-center observational study of 396 hospitalized patients with a minimum 0.5 mg/dl change in serum creatinine who were prescribed a nephrotoxic or renally eliminated medi...

Anticoagulation-associated adverse drug events.

PURPOSE Anticoagulant drugs are among the most common medications that cause adverse drug events (ADEs) in hospitalized patients. We performed a 5-year retrospective study at Brigham and Women's Hospital to determine clinical characteristics, types, root causes, and outcomes of anticoagulant-associated ADEs. METHODS We reviewed all inpatient anticoagulant-associated ADEs, including adverse dr...

Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy

The underlying molecular mechanisms of adverse drug events (ADEs) associated with cancer therapy drugs may overlap with their antineoplastic mechanisms. In a previous study, we developed an ADE-based tumor stratification framework (known as ADEStrata) with a case study of breast cancer patients receiving aromatase inhibitors, and demonstrated that the prediction of per-patient ADE propensity si...